

# Neuroendocrine tumor of the common bile duct: a case report and review of the literature

Zhong Liu<sup>1</sup>  
Deng-Yong Zhang<sup>1</sup>  
Zheng Lu<sup>1</sup>  
Pei Zhang<sup>2</sup>  
Wan-Liang Sun<sup>1</sup>  
Xiang Ma<sup>1</sup>  
Hua Wu<sup>1</sup>  
Bin-Quan Wu<sup>1</sup>  
Shuo Zhou<sup>1</sup>

<sup>1</sup>Department of General Surgery, The First Affiliated Hospital of Bengbu Medical College, Bengbu, People's Republic of China; <sup>2</sup>Department of Pharmacy, Bengbu Medical College, Bengbu, People's Republic of China

**Abstract:** We report a rare case of neuroendocrine tumor (NET) in the common bile duct (CBD). The patient is a 56-year-old female who presented to our department with symptoms of fever but without jaundice. A preoperative examination showed a tumor in the CBD. The tumor volume was almost  $5.5 \times 4.5 \times 4 \text{ cm}^3$ , which is the biggest NET in the CBD reported on PubMed. The imaging results (computed tomography [CT] and magnetic resonance imaging [MRI]) were not consistent with CBD adenocarcinoma. The tumor appeared to oppress the growth of the CBD rather than originate in the bile duct wall; combined with the low blood bilirubin index and lack of jaundice symptoms, the preoperative diagnosis was not clear. We performed a radical resection of the cholangiocarcinoma. The patient recovered well before going home. The pathology was NET (Grade 2). The patient showed no recurrence to date, without intravenous chemotherapy (8 months).

**Keywords:** bile duct adenocarcinoma, neuroendocrine tumors, bile duct


## Introduction

Neuroendocrine tumors (NETs) are rare tumors that are derived from peptidergic neurons and neuroendocrine cells. NETs can be seen in multiple organ tissues throughout the body, including the digestive tract, lung, thymus, and uterus.<sup>1</sup> NETs most often occur in the gastrointestinal tract and pancreatic tissue and are rare in the common bile duct (CBD). We report a NET that occurred in the middle of the CBD, with a volume of  $5.5 \times 4.5 \times 4 \text{ cm}^3$ . This is the biggest NET in the CBD (except for other pathologic types, such as neuroendocrine carcinoma [NEC] and mixed adenoneuroendocrine carcinoma) reported on PubMed.

## Case presentation

A 56-year-old woman was referred to our department for intermittent fever over the past 4 months. An ultrasonic inspection indicated a solid hypoechoic mass located in the hepatic hilar area close to the right side of the CBD; the intrahepatic bile duct and main pancreatic duct were expansive. Magnetic resonance imaging (MRI) indicated expanded intrahepatic and extrahepatic bile ducts, enlargement of the gallbladder, and a tumor located on the CBD with an iso-signal intensity on a T2-weighted image (Figure 1A). The computed tomography (CT) analysis indicated dilatation of the intrahepatic bile duct, the soft-tissue density in the first hilar, and that it was indistinct from the pancreas. The tumor had an inhomogeneous enhancement after enhancement during the CT detection (Figure 1B). The blood biochemical tests showed the following: alanine aminotransferase 113 U/L, aspartate transaminase 77 U/L, carbohydrate antigen 19-9 (CA19-9) 64.61 IU/mL, without any other abnormalities.

Correspondence: Zheng Lu  
Department of General Surgery, The First Affiliated Hospital of Bengbu Medical College, No 287 Chang Huai Road, Bengbu 233000, Anhui, People's Republic of China  
Tel/fax +86 552 308 6149  
Email zdy527897470@126.com



**Figure 1** Preoperative MRCP, MRI, and CT detection.


**Notes:** MRCP, MRI, and CT examinations were performed before surgery. **(A)** The mass was located in the hepatic hilum, filling the defect of the middle CBD, with dilatation of the intrahepatic and extrahepatic bile duct (red arrow). **(B)** Upper abdominal CT, both sweep phase and enhanced in the arterial phase. The tumor has an obvious reinforcement in the arterial phase.

**Abbreviations:** CBD, common bile duct; CT, computed tomography; MRCP, magnetic resonance cholangiopancreatography; MRI, magnetic resonance imaging.

## Treatment


The preoperative diagnosis was that of cholangiocarcinoma or other intraperitoneal tumor compression of the bile duct. We conducted an exploratory laparotomy and found a tough tumor located in the CBD, protruding from the wall of the bile duct to the right abdominal. The tumor was not completely blocking the bile duct lumen and there were no other tissues encroaching on the surrounding tissues, including the portal vein, hepatic artery, inferior vena cava, and pancreas. We excised the CBD 2 cm above and below the tumor with a hepatoduodenal ligament lymph node dissection. The Roux-en-Y anastomosis was conducted for the proximal bile duct and jejunum. The intraoperative pathology of the bile duct showed no tumor cells. The surgical resection specimen is shown in Figure 2.

The pathology is shown in Figure 3: NET of the bile duct (Grade [G] 2) of size  $6 \times 4.5 \times 4 \text{ cm}^3$ . Histological sections were prepared from the excised bile duct (–), and immunohistochemical staining was performed for cytokeratin ++, C7–/+, cluster of differentiation 56 +, synaptophysin (Syn) ++,



**Figure 2** The macroscopic appearance of the tumor after surgery.

**Notes:** After resection, we observed that the mass was located on the right wall of the common bile duct. The left wall of the common bile duct was incised. The black arrow shows the left side of the common bile duct, the red arrow shows the right side of common bile duct, the white arrow shows the hepatic margin of the common bile duct, and the blue arrow shows the tumor.



**Figure 3** Photomicrographs showing representative histologic sections of the tumor.

**Notes:** (A) The tumor was stained using H&E ( $\times 100$ ). (B) The tumor component was diffusely positive for the marker CD56 ( $\times 100$ ). (C) The tumor component was negative for CgA ( $\times 100$ ). (D) The tumor component was positive for Ki-67 ( $\times 100$ ). (E) The tumor component was diffusely positive for the marker Syn ( $\times 100$ ).

**Abbreviations:** H&E, hematoxylin-eosin; CD56, cluster of differentiation 56; CgA, chromogranin A; Ki-67, antigen Ki-67; Syn, synaptophysin.

$\alpha 1$  anti-chymotrypsin  $-/+$ , chromogranin A (CgA)  $-$ , antigen Ki-67 (Ki-67)  $+$  (12%). The patient has demonstrated tumor-free survival for 8 months after the operation (to date) without chemotherapy.

### Patient consent

This study was approved by the Institutional Review Board of Bengbu Medical College. The patient provided written informed consent and gave permission for the use of biopsies

and publication of case details, including publication of the images.

### Discussion

The gastrointestinal tissues are the most common site for NETs. The incidence of NET is approximately 75% of digestive tract tumors, and NEC just accounts for approximately 0.1%–0.2% of digestive tract tumors.<sup>1,2</sup> In the biliary system, the incidence of NET accounts for just 0.2%–2.0% of

tumors,<sup>3</sup> and NEC accounts for 0.19% of bile duct tumors,<sup>4</sup> because there are no neuroendocrine cells in the extrahepatic bile duct mucosa. For extrahepatic bile duct NET, the common hepatic duct and distal CBD are sites of predilection (accounting for 19.2% of bile duct tumors); the middle of the CBD accounts for 17.9% of tumors, the cystic gall duct accounts for 16.7%, and the proximal CBD accounts for 11.5%.<sup>5,6</sup> Many researchers believe that NETs are often derived from chromaffin cells and Kulchitsky cells, both of which originate from the endoderm.<sup>7</sup> The bile duct tissues rarely contain these cells, which is why bile duct NET is rare. At present, the etiology of bile duct NETs is unclear. Some studies indicate that NETs are linked with cholelithiasis and congenital malformation of the biliary tract, both of which lead to chronic inflammation.<sup>8</sup> Chronic inflammation leads to metaplasia of bile duct epithelial cells, and then metaplasia into NET.

According to previous literature,<sup>9,10</sup> cholangiocarcinoma is often located in the upper third of the bile duct and demonstrates invasive growth behavior. The pathology of most cholangiocarcinomas is that of adenocarcinoma, and CBD NETs are rare. The degree of differentiation of NETs is usually determined through immunohistochemistry. NET can be divided into three grades (G1–G3, Table 1), according to the number of mitotic images and the Ki-67 index.<sup>11</sup> Poorly differentiated NETs (also known as NECs, which are classed as G3) can be divided into three types according to the tumor cell type: large cell NEC, small cell NEC, and adenocarcinoma-NEC, which are combined with adenocarcinoma and NET cells.<sup>12,13</sup> Other rare types of NETs also exist, such as goblet cell carcinoid and tubular carcinoid.<sup>12,13</sup> Many biomarkers are used for diagnosis, such as Syn and CgA. In our case, the immunohistochemical staining results were Syn++ and CgA–, the Ki-67 was 12%, and the mitotic index was approximately 2%, indicating NET G2.

Surgical radical resection is the main treatment for choledochus NETs. The operation is classified into three types according to the position of the mass: pancreaticoduodenectomy (tumor located in the distal CBD), bile duct resection, and cholangiojejunostomy (tumor located in the middle CBD), combined with partial hepatectomy for patients who have liver metastases. The National Comprehensive Cancer Network guidelines for gastrointestinal and pancreatic NETs indicate that lymph node dissection is advocated, but there is no uniform standard for the extent of specific dissection. Furthermore, there was no uniform standard before the operation in the current study, and chemotherapy could not be performed because of the difficulty in diagnosis before

the operation. Currently, cisplatin and etoposide are often used for chemotherapy after surgery. In a study consisting of 21 patients with biliary duct and pancreatic NEC, who were treated with platinum-based chemotherapy after surgery, three were sensitive to the chemotherapy; the median progression-free survival was 1.8 months, and median overall survival was 5.8 months.<sup>21</sup> For low-grade NETs, most patients demonstrated good survival after radical surgery, and the 10-year survival rate was approximately 80%. The survival time for patients with poorly differentiated NEC is short; the majority of NEC patients, especially small-cell NEC patients, died within 1 year.<sup>4</sup> According to the 2010 WHO classification guidelines for digestive system tumors, extrahepatic bile duct NETs had metastasized in nearly 1/3 of patients at the time of diagnosis, and the 5-year survival rate was 60%–100%. The prognosis of NEC patients was very poor, with 40%–50% of patients with tumor metastasis at the time of diagnosis, and the 5-year survival rate was low.<sup>12</sup> Combined with the data reported by Michalopoulos et al, we can see that patients without lymph node dissection develop intraperitoneal organ metastasis soon after surgery; otherwise, the probability of metastasis is lower. The bile duct NET (G3) patients without postoperative chemotherapy died sooner, whereas patients who underwent postoperative chemotherapy and those who did not undergo chemotherapy had all survived at the reported follow-up time.<sup>6</sup> In our case, the patient (NET G2) has survived until now without any chemotherapy. Therefore, we believe that postoperative prophylactic intravenous chemotherapy is beneficial for NETs, especially for patients in G3. Many more clinical trials are ongoing, and these results will clarify this point.

In this case, the patient presented to our ward with fever. The ultrasound analysis found a tumor in the extrahepatic bile duct without the symptom of jaundice (we speculate that the bile duct was not blocked completely by the exophytic tumor). CT and MRI indicated a bile duct tumor; the levels of CA19-9 in the blood were high. We first considered the possibility of cholangiocarcinoma. However, when we considered the uncommon symptoms and CT results the enhancement degree of CT in the arterial phase for cholangiocarcinoma is lower than for the liver, and it is often a delayed enhancement. In this case, the enhancement was early. In addition, the tumor demonstrated exophytic growth, which is unusual in bile duct cholangiocarcinoma. We had doubts about the diagnosis of bile duct cancer before surgery. Some clinicians consider that a biopsy of an endoscopic retrograde cholangiopancreatography (ERCP) for a bile duct mass is a reasonable diagnostic method, which helps

**Table 1** The common bile duct NETs previously published in PubMed

Case	Year	Sex/ age	Size (cm)	Location	Symptom	Invasion	Treatment	Immunohistochemistry	Follow-up (years)
1	1961	F/55	n/a	CBD	Weakness	No	Lap-B	Argentaf+	n/a
2	1968	F/41	n/a	PCBD	Jaundice, pain	PV, liver	Lap-B	Argentaf+	3 W, death
3	1978	F/72	2×1.5×1	DCBD	Jaundice	No	n/a	Argentaf+	n/a
4	1979	M/32	3×4	PCBD	Jaundice	No	BDR	Argentaf+	n/a
5	1981	M/30	1.5	DCBD	Jaundice, diarrhea	LN	PD	GI+	48 Mo, alive
6	1987	F/65	1	PCBD	Jaundice, Ch	Liver	TR	Argentaf+	5 Mo, alive
7	1988	F/71	2.5	CBD	Jaundice, pain	No	PD	Chrom+, NSE+	12 Mo, alive
8	1990	F/38	2	CBD	Jaundice, pain, Ch Weakness, vomiting	No	Choledochotomy Ch-C, TR, T-tube	Chrom+	n/a
9	1990	M/30	1.5	PCBD	Jaundice, VHLS Itching	No	CH-C, BDR HJ R-Y	PGP9.5+, gastrin+ S100+, CCK+, 5-HT+	n/a
10	1991	F/39	1.5	CBD	Jaundice, vomiting Itching, pain, diarrhea	No	BDR, LNR HPD-AT, CH-C	Chrom+, 5-HT+ SS+, GI+	42 Mo, alive
11	1992	F/15	n/a	DCBD	Jaundice, pain	No	PPPD	5-HT+, PP+, GG+	48 Mo, alive
12	1992	F/60	1.5×1.5	CBD	CBDC	No	TR, Segmentectomy	Chrom+	n/a
13	1995	F/47	2	PCBD	I-F	No	Trisegmentectomy BDR, HJ R-Y	Chrom+	48 Mo, alive
14	1995	F/53	2.2×2	DCBD	Jaundice, pain, Ch Nausea	No	CH-C, TR	Chrom+, Sph+, GI+ NSE+, cPP+, 5-HT+	8 Mo, alive
15	1996	M/78	1.5×0.6×0.8	PCBD	Jaundice, itching	No	BDR, LNR, HJ R-Y	Chrom+	15 Mo, alive
16	1996	F/44	0.5	CBD	Jaundice	Liver	L-M resection, PPPD	Chrom+	18 Mo, alive
17	1996	M/42	1.3×1.1×1.6	CBD	I-F	No	Orthotopic liver Transplantation	Chrom+, 5-HT+ gastrin+	9 Mo, alive
18	1999	F/65	2–3	DCBD	Jaundice, pain, Ch-C Pruritus, diarrhea	LN	PD	Chrom+, NSE+	17 Mo, alive
19	2000	M/43	4×3×2.3	DCBD	Jaundice, pain	No	PD (Whipple)	Chrom+, gastrin+	42 Mo, alive
20	2000	F/42	1.1	CBD	Jaundice, pruritus	No	BDR, HJ R-Y	Chrom+, SS+	132 Mo, alive
21	2000	F/n/a	1.4	CBD	Jaundice, pain	LN	BDR, LNR, HJ R-Y	Chrom+, gastrin+	120 Mo, alive
22	2003	M/59	1×2	PCBD	Jaundice	LN	BDR, HJ	Argentaf+	6 Mo, alive
23	2003	M/65	2.2×2×1.7	DCBD	I-F, Ch	No	BDR, HJ	Chrom+, NSE+	37 Mo, alive
24	2003	M/19	1×0.4	PCBD	Jaundice, pain, Ch	No	BDR, HJ	Chrom+, LMW-, Cytk+	12 Mo, alive
25	2004	M/79	0.2	DCBD	Jaundice	Live, LN	PPPD	Grimelius+, F-M, Chrom	34 Mo, alive
26	2005	F/38	3×4×3	CBD	Jaundice, pain, Ch	No	BDR, LNR, HJ	Cytk+	2 Mo, alive
27	2006	M/30	1.8×1×0.7	DCBD	Jaundice, diarrhea Pruritus, weight loss	No	PPPD	Chrom+, Sph+, NSE+ 5-HT+, Cytk+, Ki-67: 6%	84 Mo, alive
28	2006	F/67	1.6×1.5×0.5	DCBD	Jaundice, pain	LI	PPPD	Chrom+, Sph+, CD56+	10 Mo, alive
29	2006	F/40	0.7	CBD	Jaundice, pain, Ch-C	LN, LI	BDR	Chrom+	14 Mo, death
30	2006	F/67	n/a	CBD	Jaundice	n/a	PD (Whipple)	Chrom+, Sph+, NSE+	n/a
31	2006	M/76	1.4×1	DCBD	Jaundice, pain	Liver	PD (Whipple)	Chrom+, Sph+, GI+	8 Mo, alive
32	2007	M/51	2.5×2.2×2.8	PCBD	Weight loss	No	BDR, LNR, HJ R-Y	Chrom+, Sph+	22 Mo, alive
33	2007	M/73	1×1.2×0.7	DCBD	Pain, fever	No	PPPD	Chrom+, Sph+, NSE+	12 Mo, alive
34	2007	M/52	2	CBD	Jaundice	No	BDR, LNR, HJ R-Y	Chrom+, Sph+	41 Mo, alive
35	2008	F/31	1×1.2	CBD	Jaundice, VHLS	No	BDR, LNR, HJ R-Y	NSE+	n/a
36	2009	F/33	n/a	DCBD	MEN-I, ZES	Liver	TR, T tube, LNR RFA for L-M	Chrom+, gastrin+	24 Mo, alive
37	2010	M/10	1×1.5×2	DCBD	Jaundice, pain	No	LNR, PD	Chrom+	12 Mo, alive
38	2011	M/42	1.8	DCBD	Jaundice, pain	No	PD	Chrom+, Sph+	n/a
39 <sup>14</sup>	2015	M/61	2.7×2.1	CBD	Jaundice	No	Chemotherapy BD resection	Ki-67: 90%, p53+ Pan-keratin+ KOC+, S100P+	3 Mo, LN metastasis alive
40 <sup>15</sup>	2016	M/72	3×3×2.5	CBD	Jaundice	RHA	RHP, BDR, PTPVE Chemotherapy	CD56+, Syn+ Ki-67: 56.2%	7 Mo, L-M alive

(Continued)

**Table 1** (Continued)

Case	Year	Sex/ age	Size (cm)	Location	Symptom	Invasion	Treatment	Immunohistochemistry	Follow-up (years)
41 <sup>16</sup>	2016	M/80	2.4×1.9	CBD	Jaundice	HDLLN	BDR LD dissection	CD56+, Syn+ Ki-67: 72%	3 Mo, L-M death
42 <sup>17</sup>	2016	M/38	2	PCBD	Jaundice, asthenia	No	BDR LN dissection	CD56+, CK7+, CgA+ Syn+, Ki-67: 15%	n/a
43 <sup>18</sup>	2016	F/51	1.5×1.2	DCBD	Jaundice	No	BDR LN dissection	CgA-, Ki-67≤2%	3 W, alive
44 <sup>19</sup>	2017	M/64	1.3×1.1×1	PCBD	Jaundice	No	BDR HJ R-Y	CD 56+, Ki67=5% CgA+, Syn+	n/a
45 <sup>20</sup>	2017	M/45	4	PCBD	Jaundice Abdominal pain	LN	BDR LN dissection	Ki-67: 4% CgA-, 5-HT	6 Mo, alive
46*	2017	F/56	5.5×4.5×4	CBD	Fever	No	HJ R-Y, BDR	CD56+, CK+, Syn+	8 Mo, alive

**Notes:** \*Our case. For Case 1–38, refer to Michalopoulos et al (Table 1).<sup>6</sup>

**Abbreviations:** BDR, bile duct resection; CBD, common bile duct; CBDC, congenital bile duct cyst; CCK, cholecystokinin; Ch, cholelithiasis; Ch-C, cholecystectomy; Chrom, chromogranin A; Cyt, cytokeratin; DCBD, distal common bile duct; F, female; GG, glucagon; Gl, Grimelius; HDLLN, hepatoduodenal ligament lymph node; HJ, hepaticojunostomy; HJ R-Y, hepaticojunostomy Roux en Y; HPD-AT, hepaticoduodenal anastomosis; I-F, incidental finding; Lap-B, laparotomy-biopsy; LI, local invasion; L-M, liver metastasis; LN, lymph node; LNR, lymph node resection; M, male; MEN-1, multiple endocrine neoplasia syndrome type 1; Mo, month; n/a, not available; NETs, neuroendocrine tumors; PCBD, proximal common bile duct; PD, pancreatoduodenectomy; PP, pancreatic polypeptide; PPPD, pylorus preserving pancreaticoduodenectomy; PTPVE, percutaneous transhepatic portal vein embolization; PV, portal vein; RFA, radio-frequency ablation; RHA, right hepatic artery; RHP, right hemihepatectomy; Sph, synaptophysin; SS, somatostatin; TR, tumor resection; VHLS, Von Hippel–Lindau syndrome; W, weeks; ZES, Zollinger–Ellison syndrome; 5-HT, serotonin.

to characterize a tumor and guide subsequent surgery. However, we did not consider ERCP, as the bile duct biopsy may cause complications such as bile leakage. Such patients must undergo surgery to remove the tumor and so we conducted an exploratory laparotomy (preparing for radical resection of bile duct cancer). The postoperative pathologic diagnosis was NET (G2).

NETs (G1–G3, except for any other pathologic types) in extrahepatic bile ducts are rare. We found no more than 100 cases on PubMed. PubMed contains just 45 cases of NETs in the CBD (except for NETs in the gallbladder and cystic duct, ampulla, main bile duct, and left or right hepatic ducts in the liver and also except for any other pathology, such as adenocarcinoma-NET). Michalopoulos et al reported approximately 38 cases from 1961 to 2013.<sup>6</sup> Combining the cases from Michalopoulos et al and the other 8 cases of NET of the CBD, 48 cases are included in Table 1. We found that bile duct NETs do not have an endocrine function. Patients with non-functional NETs in the CBD often have the symptom of jaundice first, with or without the symptom of fever and abdominal discomfort. Because of the absence of a specific symptom, NETs in the CBD are often considered to be cholangiocarcinoma, leading to a misdiagnosis.

The WHO has made a classification for extrahepatic and gallbladder tumors, including the bile duct and gallbladder NETs. However, there are no uniform guidelines for NET treatment, especially for radiotherapy and chemoradiotherapy postoperatively. It is useful to report this uncommon tumor. If more cases were reported, uniform guidelines for the

treatment of NET of the CBD could be established. In conclusion, patients with CBD NETs of G1–2 demonstrate good survival after resection without chemotherapy. We recommend lymph node dissection for NET of the CBD.

## Acknowledgment

This study was supported by the Key Research and Development Plan of Anhui Province, People's Republic of China (1604a0802088).

## Disclosure

The authors report no conflicts of interest in this work.

## References

- Liang HJ. Diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. *Chin J Digest Surg*. 2014;13:756–759. Chinese.
- Albores-Saavedra J, Murakata L, Krueger JE, Henson DE. Noninvasive and minimally invasive papillary carcinomas of the extrahepatic bile ducts. *Cancer*. 2000;89(3):508–515.
- Bosman FT, Carneiro F, Hruban RH, Theise ND. *WHO Classification of Tumours of the Digestive System*. Lyon: IARC Press. 2010;195–334.
- Albores-Saavedra J, Batich K, Hossain S, Henson DE, Schwartz AM. Carcinoid tumors and small-cell carcinomas of the gallbladder and extrahepatic bile ducts: a comparative study based on 221 cases from the Surveillance, Epidemiology and End Results Program. *Ann Diagn Pathol*. 2009;13(6):378–383.
- Hosoda K, Kobayashi A, Shimizu A, et al. Neuroendocrine tumor of the common bile duct. *Surgery*. 2016;160:525–526.
- Michalopoulos N, Papavramidis TS, Karayannopoulou G, Pliakos I, Papavramidis ST, Kanellos I. Neuroendocrine tumors of the extrahepatic biliary tract. *Pathol Oncol Res*. 2014;20(4):765–775.
- Takahashi K, Sasaki R, Oshiro Y, Fukunaga K, Oda T, Ohkohchi N. Well-differentiated endocrine carcinoma originating from the bile duct in association with a congenital choledochal cyst. *Int Surg*. 2012;97(4): 315–320.

8. Park SB, Moon SB, Ryu YJ, et al. Primary large cell neuroendocrine carcinoma in the common bile duct: first Asian case report. *World J Gastroenterol*. 2014;20(47):18048–18052.
9. Hong N, Kim HJ, Byun JH, et al. Neuroendocrine neoplasms of the extrahepatic bile duct: radiologic and clinical characteristics. *Abdom Imaging*. 2015;40(1):181–191.
10. Sasatomi E, Nalesnik MA, Marsh JW. Neuroendocrine carcinoma of the extrahepatic bile duct: case report and literature review. *World J Gastroenterol*. 2013;19(28):4616–4623.
11. Kulke MH, Shah MH, Benson AB, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®: Neuroendocrine Tumors). Version 2. <http://guide.medlive.cn/guideline/13095>. Accessed March 29, 2017.
12. Rindi G, Petrone G, Inzani F. The 2010 WHO classification of digestive neuroendocrine neoplasms: a critical appraisal four years after its introduction. *Endocr Pathol*. 2014;25:186–192.
13. Kihara Y, Yokomizo H, Urata T, et al. A case report of primary neuroendocrine carcinoma of the perihilar bile duct. *BMC Surg*. 2015;15:125.
14. Aigner B, Kornprat P, Schöllnast H, et al. A case of focal small-cell neuroendocrine carcinoma in the vicinity of the extrahepatic bile duct, adjacent to an extensive biliary intraepithelial neoplasm: a diagnostic challenge with major clinical implications. *Anticancer Res*. 2015;35:4821–4828.
15. Oshiro Y, Gen R, Hashimoto S, et al. Neuroendocrine carcinoma of the extrahepatic bile duct: a case report. *World J Gastroenterol*. 2016;22:6960–6964.
16. Murakami M, Katayama K, Kato S, et al. Large-cell neuroendocrine carcinoma of the common bile duct: a case report and a review of literature. *Surg Case Rep*. 2016;2:141.
17. Sánchez Cabús S, Pittau G, Sebah M. Primary non-functioning neuroendocrine tumor of the extrahepatic bile duct. *Rev Esp Enferm Dig*. 2016;109:228–229.
18. Raspanti C, Falco N, Silvestri V, et al. Neuroendocrine tumor of the common bile duct: case report. *G Chir*. 2016;37:275–280.
19. Khan FA, Stevens-Chase A, Chaudhry R, et al. Extrahepatic biliary obstruction secondary to neuroendocrine tumor of the common hepatic duct. *Int J Surg Case Rep*. 2017;30:46–49.
20. Hoepfner L, White JA. Primary extrahepatic bile duct neuroendocrine tumor with obstructive jaundice masquerading as a Klatskin tumor. *J Surg Case Rep*. 2017;6:1–3.
21. Iwasa S, Morizane C, Okusaka T, et al. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. *Jpn J Clin Oncol*. 2010;40:313–318.

## OncoTargets and Therapy

### Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on

Submit your manuscript here: <http://www.dovepress.com/oncotargets-and-therapy-journal>

patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress